# Leucid Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leucid-bio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.leucid.com
- Total disclosed funding: $21M
- Latest round: Series A (Sep 24, 2021)
- Investors on record: 5

## About

Leucid Bio Ltd is a biotechnology company focused on developing advanced CAR-T therapies using its proprietary Lateral CAR platform to enhance the effectiveness of cancer treatments.Founded in 2014, Leucid Bio Ltd operates from London, UK, specializing in CAR-T therapies. The company has undergone strategic developments, including a significant focus on its lead candidate, LEU011, targeting various cancers. The firm has received GBP 11.58 mn in Series A funding on September 24, 2021, from investors including Vulpes Investment Management and Epidarex Capital. The CEO, Filippo Petti, leads the company in advancing its cancer therapy initiatives.Leucid Bio specializes in the development of advanced CAR-T therapies, primarily leveraging its proprietary Lateral CAR platform, designed to enhance the efficacy and safety of T-cell therapies. The flagship product, LEU011, is an autologous CAR-T therapy targeting NKG2D stress ligands, prevalent in over 80% of human tumor cells, making it applicable for various cancers. The Lateral CAR technology, based on over two decades of research led by Dr. John Maher at King's College London, focuses on reprogramming T-cells to effectively eliminate cancer cells. Intended primarily for patients with refractory cancers, these therapies aim to improve treatment outcomes and extend survival rates, targeting markets in North America and Europe.Leucid Bio generates revenue through partnerships and collaborations with healthcare institutions that administer specialized cancer therapies. Revenue streams typically involve the provision of LEU011 and other products to clinical trial sites and healthcare providers. The company’s revenue model includes exclusive distribution rights, collaborative research funding, and milestone payments associated with its therapies. As the company advances its CAR-T pipeline, establishing successful clinical outcomes and market adoption will be critical for revenue generation, particularly with LEU011 in clinical trials.Following the GBP 11.58 mn funding raised in September 2021, Leucid Bio Ltd plans to initiate a Phase 1 trial of its lead candidate, LEU011, targeting platinum-resistant ovarian cancer. The company aims to expand its market presence primarily across North America and Europe, leveraging its innovative treatment strategies to address unmet medical needs in oncology.

## Funding rounds

- Series A, Sep 24, 2021, $16M — Sofinnova Partners, British Business Bank, Epidarex Capital, Vulpes Investment Management, 2Invest
- Seed, Dec 20, 2019, $2.6M — Sofinnova Partners, Epidarex Capital
- Seed, Jul 3, 2017, $2.9M — Sofinnova Partners, Epidarex Capital

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Seed, Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A
- Vulpes Investment Management (https://capitalatlas.ai/funds/vulpes-investment-management) — Series A
- 2Invest — Series A